Marked suppression of the activity of some, but not all, antifolate compounds by augmentation of folate cofactor pools within tumor cells (Q43557342)

24 November 2017

title

Marked suppression of the activity of some, but not all, antifolate compounds by augmentation of folate cofactor pools within tumor cells (English)

1 reference

24 November 2017

1 reference

Zhao R

1

1 reference

24 November 2017

Gao F

series ordinal

2

1 reference

24 November 2017

Goldman ID

series ordinal

3

1 reference

24 November 2017

language of work or name

English

0 references

publication date

1 April 2001

1 reference

24 November 2017

published in

Biochemical Pharmacology

1 reference

24 November 2017

volume

61

1 reference

24 November 2017

issue

7

1 reference

24 November 2017

page(s)

857-865

1 reference

Mutations in the reduced folate carrier gene which confer dominant resistance to 5,10-dideazatetrahydrofolate

24 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900532-9

Loss of Folic Acid Exporter Function with Markedly Augmented Folate Accumulation in Lipophilic Antifolate-resistant Mammalian Cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900532-9

Relationships between carrier-mediated transport of folate compounds by L1210 leukemia cells: evidence for multiplicity of entry routes with different kinetic properties expressed in plasma membrane vesicles.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900532-9

A reduced folate carrier mutation produces substrate-dependent alterations in carrier mobility in murine leukemia cells and methotrexate resistance with conservation of growth in 5-formyltetrahydrofolate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900532-9

Discrimination among reduced folates and methotrexate as transport substrates by a phenylalanine substitution for serine within the predicted eighth transmembrane domain of the reduced folate carrier

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900532-9

Impact of overexpression of the reduced folate carrier (RFC1), an anion exchanger, on concentrative transport in murine L1210 leukemia cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900532-9

Determinants of the disparate antitumor activities of (6R)-5,10-dideaza-5,6,7,8-tetrahydrofolate and methotrexate toward human lymphoblastic leukemia cells, characterized by severely impaired antifolate membrane transport.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900532-9

The effect of folic acid fortification on plasma folate and total homocysteine concentrations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900532-9

Biochemical pharmacology of the lipophilic antifolate, trimetrexate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900532-9

Polyglutamation of methotrexate. Is methotrexate a prodrug?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900532-9

Synthesis and potent antifolate activity and cytotoxicity of B-ring deaza analogues of the nonpolyglutamatable dihydrofolate reductase inhibitor Nalpha-(4-amino-4-deoxypteroyl)-Ndelta-hemiphthaloyl- L-ornithine (PT523).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900532-9

Tight binding of folate substrates and inhibitors to recombinant mouse glycinamide ribonucleotide formyltransferase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900532-9

Structural features of 5,10-dideaza-5,6,7,8-tetrahydrofolate that determine inhibition of mammalian glycinamide ribonucleotide formyltransferase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900532-9

Biochemistry and pharmacology of glycinamide ribonucleotide formyltransferase inhibitors: LY309887 and lometrexol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900532-9

Mammalian folylpoly-gamma-glutamate synthetase. 4. In vitro and in vivo metabolism of folates and analogues and regulation of folate homeostasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900532-9

Studies with a mathematical model of folate metabolism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900532-9

Cellular folates prevent polyglutamation of 5, 10-dideazatetrahydrofolate. A novel mechanism of resistance to folate antimetabolites

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900532-9

Phase I study of (6R)-5,10-dideazatetrahydrofolate: a folate antimetabolite inhibitory to de novo purine synthesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900532-9

Whole-body disposition and polyglutamate distribution of the GAR formyltransferase inhibitors LY309887 and lometrexol in mice: effect of low-folate diet

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900532-9

Dietary folate and folylpolyglutamate synthetase activity in normal and neoplastic murine tissues and human tumor xenografts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900532-9

A phase I clinical study of the antipurine antifolate lometrexol (DDATHF) given with oral folic acid.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900532-9

Weekly lometrexol with daily oral folic acid is appropriate for phase II evaluation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900532-9

10.1016/S0006-2952(01)00532-9

7 January 2021

Identifiers

DOI

1 reference

24 November 2017

1 reference